Inhibin and the regulation of bone mass.
Inhibins A and B are gonadal peptide members of the transforming growth factor-beta superfamily that serve as negative feedback regulators of pituitary follicle-stimulating hormone (FSH). Accumulating evidence suggests that bone turnover and bone loss increase in women before menopause and the decrease in serum estradiol levels. Increased FSH levels have been correlated with some of these perimenopausal changes, whereas decreased inhibins strongly correlate with increases in bone formation and resorption across the menopause transition, and predict lumbar bone mass in perimenopausal women, likely resulting from the direct inhibin suppression of osteoblast and osteoclast development. Interestingly, continuous exposure of mice to inhibin A in vivo is anabolic and protective against gonadectomy-induced bone loss. Together, these data suggest inhibins contribute to the endocrine regulation of bone metabolism via a bimodal mechanism of action such that cycling inhibin exposure suppresses bone turnover, and continuous exposure to inhibins is anabolic.
Gaddy
Dana
D
Department of Physiology, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 505, Little Rock, AR 72205, USA. gaddydana@uams.edu
D000818:Animals; D015519:Bone Density / Q000502:physiology*; D001842:Bone and Bones / Q000378:metabolism*; D004195:Disease Models, Animal; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007265:Inhibins / Q000502:physiology*; D051379:Mice; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism
D007265:Inhibins; D005640:Follicle Stimulating Hormone
J Biol Chem. 2008 Mar 21;283(12):7628-37
18184661
Semin Reprod Med. 2004 Aug;22(3):269-76
15319829
Endocrine. 2002 Feb;17(1):29-36
12014700
J Clin Endocrinol Metab. 1996 Jul;81(7):2742-5
8675606
Bone. 1999 Feb;24(2):121-4
9951780
Nature. 2000 Mar 23;404(6776):411-4
10746731
Metabolism. 1976 Aug;25(8):909-55
181659
Novartis Found Symp. 2002;242:247-59; discussion 260-4
11855691
J Clin Endocrinol Metab. 1998 Jul;83(7):2266-74
9661593
Endocrinology. 2002 Jan;143(1):74-83
11751595
J Clin Endocrinol Metab. 1999 Jan;84(1):105-11
9920069
Osteoporos Int. 1998;8(3):282-90
9797914
J Clin Endocrinol Metab. 1996 Apr;81(4):1401-5
8636341
Ann N Y Acad Sci. 2004 Dec;1038:142-7
15838109
J Biol Chem. 2001 May 4;276(18):14588-96
11278442
Trends Mol Med. 2005 Feb;11(2):76-81
15694870
Mol Cell Biol. 1991 Jan;11(1):250-8
1846021
J Bone Miner Res. 1999 Feb;14(2):178-86
9933470
J Clin Invest. 2006 Aug;116(8):2152-60
16878176
Endocrinology. 2004 Apr;145(4):1835-41
14691012
Endocrinology. 2006 Dec;147(12):5592-9
16935844
J Bone Miner Res. 2008 Feb;23(2):205-14
17937534
Mol Endocrinol. 1997 Nov;11(12):1832-45
9369451
Mol Cell Endocrinol. 2004 Oct 15;225(1-2):29-36
15451565
J Clin Invest. 1998 Jul 15;102(2):274-82
9664068
J Clin Endocrinol Metab. 2006 May;91(5):1848-54
16449331
Mol Endocrinol. 2000 Jul;14(7):1075-85
10894156
Recent Prog Horm Res. 2002;57:385-409
12017554
J Endocrinol. 2005 Dec;187(3):311-25
16423810
J Clin Endocrinol Metab. 1996 Sep;81(9):3366-71
8784098
Cell. 2006 Apr 21;125(2):247-60
16630814
J Bone Miner Res. 1996 Apr;11(4):440-5
8992874
Maturitas. 2005 Oct 16;52(2):147-53
16186077
Cell Struct Funct. 1995 Oct;20(5):319-30
8581988
Endocrinology. 2006 Jul;147(7):3462-71
16601134
J Clin Endocrinol Metab. 1997 May;82(5):1522-7
9141544
Recent Prog Horm Res. 2002;57:257-75
12017547
Curr Opin Pharmacol. 2005 Dec;5(6):612-7
16181808
J Bone Miner Res. 2004 Dec;19(12):1945-54
15537436
Endocr Rev. 2000 Apr;21(2):115-37
10782361
J Biol Chem. 1988 Nov 25;263(33):17225-8
2903159
Mayo Clin Proc. 2000 Jan;75 Suppl:S46-50
10959216
Endocrinology. 2007 Apr;148(4):1654-65
17194739